Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
November 09 2023 - 9:20AM
Clearmind Medicine Inc. is pleased to announce that the company has
entered into a Clinical Trial Agreement with Johns Hopkins
University School of Medicine, to conduct its Phase I/IIa clinical
trial of its proprietary MEAI-based CMND-100 as a potential
treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical
trial is a multinational, multi-center, single- and multiple-dose
tolerability, safety and pharmacokinetic study in healthy
volunteers and AUD subjects.
Clearmind’s flagship treatment is focused on AUD,
which is an extremely common and devastating condition. The
addiction varies from mild to acute and describes a person’s
inability to control their alcohol consumption, despite negative
health, social and occupational consequences. In the clinical
trial, oral capsules will be administered once daily for ten
consecutive days. The patients will report their drinking patterns
and craving for alcohol (and cigarettes) during the clinical trial
period. Patients will also be monitored for their depression
symptoms.
Johns Hopkins University School of
Medicine is the second US-based medical site to join the Company’s
clinical trial. The first US-based site was Yale School of
Medicine’s Department of Psychiatry.
The potential of psychedelic drugs to treat various
neuropsychiatric indications is currently being explored in
multiple human clinical trials. In Clearmind’s phase I/IIa trial,
CM-CMND-001, the primary endpoint of the clinical trial is to find
the tolerable dose and characterize the safety and
pharmacokinetics/pharmacodynamics (PK/PD) of single and repeated
doses of CMND-100 in healthy subjects and those with AUD. The
secondary endpoint is to evaluate the efficacy of CMND-100 in
reduction of drinking patterns and cravings, in individuals with
moderate-to-severe AUD. Depression symptoms will also be evaluated
as an exploratory endpoint.
About Clearmind Medicine
Inc.
Clearmind is a psychedelic pharmaceutical biotech company
focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently consists of
fourteen patent families. The Company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the
Canadian Securities Exchange under the symbol "CMND" and the
Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relationsinvest@clearmindmedicine.comTelephone: (604)
260-1566US: CMND@crescendo-ir.com
General
InquiriesInfo@Clearmindmedicine.comwww.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses of its proprietary
MEAI-based CMND-100 as a potential treatment for Alcohol Use
Disorder and the potential of psychedelic drugs to treat various
neuropsychiatric indications. Forward-looking statements are not
historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and
uncertainties affecting the Company, reference is made to the
Company’s reports filed from time to time with the Securities and
Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F filed
with the SEC on February 6, 2023. Forward-looking statements speak
only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual
results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information
except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no
inference should be drawn that the Company will make additional
updates with respect thereto or with respect to other
forward-looking statements. References and links to websites have
been provided as a convenience, and the information contained on
such websites is not incorporated by reference into this press
release. Clearmind is not responsible for the contents of
third-party websites.
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From Apr 2024 to May 2024
Clearmind Medicine (NASDAQ:CMND)
Historical Stock Chart
From May 2023 to May 2024